Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
about
Tracheal development and the von Hippel-Lindau tumor suppressor homolog in DrosophilaTumor suppressor protein VHL inhibits Hedgehog-Gli activation through suppression of Gli1 nuclear localizationPrevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort studyAtlas on substrate recognition subunits of CRL2 E3 ligasesLow CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinomaOxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor proteinIdentification of 3 novel VHL germ-line mutations in Danish VHL patientsRalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program.Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near futureThe von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.VHL, the story of a tumour suppressor gene.Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3.The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.The multifaceted von Hippel-Lindau tumour suppressor protein.Ubiquitin pathway in VHL cancer syndrome.HIF hydroxylation and the mammalian oxygen-sensing pathwayTwo sides to every story: the HIF-dependent and HIF-independent functions of pVHL.The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.HIF-2alpha downregulation in the absence of functional VHL is not sufficient for renal cell differentiation.Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein.A novel VHLα isoform inhibits Warburg effect via modulation of PKM splicing.Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cellsEndocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motilityStructural insights into the folding defects of oncogenic pVHL lead to correction of its function in vitro.VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.Diagnostic genetics at a distance: von hippel-lindau disease and a novel mutation.Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products.Expression of VHL Causes Three-Dimensional Morphological Changes in Renal Cells Indicative of Proximal Tubule Differentiation.Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?Molecular aspects of renal cell carcinoma: a review.Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma.Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain.Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including TGFB1 and MMP13.DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53.Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma.The HIF and other quandaries in VHL disease.
P2860
Q22254253-7EF13BB3-E415-41E2-9AC8-C19880E47D23Q24315847-FAED11F7-B094-4F08-9C3C-A78369271564Q24813050-A87554A6-B875-400B-BA95-964748A38A66Q26750863-F3E520E1-0479-4C30-825A-A8BBDF6C651CQ27851432-C7F884A2-038C-4F06-9DE3-E6AB89D64DCAQ28647626-D4963163-83C1-4741-AFCD-A2B9C88F31C1Q31072855-5DEEB619-E6AF-45C8-A6D0-E77E262DAD09Q33292271-DCBE41C3-11A5-40CE-96E4-64735C54D389Q33481999-CD71C216-5B72-48A8-9FE5-3AD27CC348EEQ33599713-285A2C93-7D6D-4DDB-96E5-998671762EADQ34087732-D578977D-40C4-4EAF-833F-3C65B5C5E7AAQ34323668-B8ED0E6C-8936-4FE2-BD7C-4365B58AC234Q34455226-A909FAE0-576D-402E-AEA2-67222C7159ADQ34530199-75B1F429-65CF-4F00-9F10-D7821B14426FQ34569182-845B91B4-3782-4FA3-84BA-7370551626D7Q34569380-0D84EF20-7752-4501-A5A0-7D4D0AD8224AQ34660062-0D44AF8A-D95B-4315-A661-D1D7797C0DF8Q35082720-2B4E313C-19E5-4BCD-9269-C41617974B4DQ35086143-AAC66B1B-58A1-49DA-9243-36B48F5129FEQ35589987-A655D17B-01EE-48B1-A7A1-65114F9344E9Q35794374-B133D2C3-2058-4AA7-929F-EDD950EB6420Q35891283-1BA59982-04E6-4463-B084-FD6779468B93Q35891379-B25D1CDE-81A8-43C9-B532-F8AFFA001845Q36089988-8F64E4A4-0FD2-44BD-8E2D-1016A5EEF079Q36549605-DAD88B57-7AF3-44A3-B794-5D7BA23C70C7Q36632436-3124FC66-BD81-4ABC-8071-1C28E4A268FCQ36945200-6454E50C-4480-4C0C-B458-EEF2F117C3ECQ37038901-22ECA724-CA89-475E-9896-029E0EA23B89Q37156131-C863F2A8-F370-4B03-B835-51C3AE47DA05Q37230912-DBAEA94F-2FBC-4E42-BEC8-F88B2C41004BQ37354454-9E13959F-8852-4B05-BDDB-2967ECF82BB1Q37575635-688A77D9-EB90-4D95-9A7C-4D886C9CBCD5Q37942072-E4ADF466-0953-49BA-950F-94EB6697E99AQ40074094-2CFA3CF2-1682-46CA-A2B7-A9BE31DD946DQ40436447-70A1D539-F63D-43B8-8D01-9471EA21DB5AQ41574276-28527E28-89E9-4498-9053-B860FD366494Q43244499-DD35C3EA-6FF5-4898-8A29-8ACD9F157D8BQ44165063-0A229E7A-9C90-4A92-9136-983FA554F1BDQ47282416-FB141596-CAC1-416D-9FE0-201A3EE8E0BEQ50026055-7A97DB38-B6E7-46ED-B568-9D4FABCA801D
P2860
Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Alternate choice of initiation ...... ith tumor suppressor activity.
@en
Alternate choice of initiation ...... ith tumor suppressor activity.
@nl
type
label
Alternate choice of initiation ...... ith tumor suppressor activity.
@en
Alternate choice of initiation ...... ith tumor suppressor activity.
@nl
prefLabel
Alternate choice of initiation ...... ith tumor suppressor activity.
@en
Alternate choice of initiation ...... ith tumor suppressor activity.
@nl
P2093
P2860
P356
P1433
P1476
Alternate choice of initiation ...... ith tumor suppressor activity.
@en
P2093
B Seizinger
C Blankenship
J G Naglich
J M Whaley
P2860
P2888
P304
P356
10.1038/SJ.ONC.1202473
P407
P577
1999-02-01T00:00:00Z
P5875
P6179
1039531850